Viking Therapeutics (VKTX) Notes Payables (2014 - 2018)

Viking Therapeutics has disclosed Notes Payables across 5 years of filings, most recently posting $3.7 million for Q1 2018.

• Notes Payables for Q1 2018 came in at $3.7 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2018 was $3.7 million (changed N/A YoY), and the FY2017 annual result was $3.5 million, up 5.55% from the prior year.
• Notes Payables came in at $3.7 million for Q1 2018 at Viking Therapeutics, up from $3.5 million in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $3.7 million in Q1 2018 to a low of $304274.0 in Q4 2014.
• The 5-year median for Notes Payables is $2.5 million (2015), against an average of $2.4 million.
• Across the five-year window, Notes Payables surged 721.63% in 2015 and increased 5.55% in 2017, its largest moves.
• Viking Therapeutics' Notes Payables stood at $304274.0 in 2014, then soared by 721.63% to $2.5 million in 2015, then jumped by 30.78% to $3.3 million in 2016, then advanced by 5.55% to $3.5 million in 2017, then advanced by 7.82% to $3.7 million in 2018.
• The last three Notes Payables figures came in at $3.7 million (Q1 2018), $3.5 million (Q4 2017), and $3.2 million (Q3 2017), per Business Quant data.